Regencell Bioscience Holdings Limited

NasdaqCM RGC

Regencell Bioscience Holdings Limited Price to Earnings Ratio (P/E) on December 05, 2024

Regencell Bioscience Holdings Limited Price to Earnings Ratio (P/E) is NA on December 05, 2024, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Regencell Bioscience Holdings Limited 52-week high Price to Earnings Ratio (P/E) is -10.20 on October 24, 2024, which is NA below the current Price to Earnings Ratio (P/E).
Regencell Bioscience Holdings Limited 52-week low Price to Earnings Ratio (P/E) is -16.16 on October 29, 2024, which is NA below the current Price to Earnings Ratio (P/E).
Regencell Bioscience Holdings Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is -12.31.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: RGC

Regencell Bioscience Holdings Limited

CEO	Mr. Yat-Gai Au
IPO Date	July 16, 2021
Location	Hong Kong
Headquarters	First Commercial Building
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals Research & Consulting

Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Key trends

Past 5 years